Akebia Therapeutics, Inc. today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference, which will take place as a virtual event on Tuesday, July 25, 2023.
| CAMBRIDGE, Mass., July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference, which will take place as a virtual event on Tuesday, July 25, 2023.
During the fireside chat, Mr. Butler will discuss recent regulatory updates regarding vadadustat, Akebia’s oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. A webcast of the presentation can be accessed through the Investors section of Akebia’s website at https://ir.akebia.com for approximately 90 days following the conference. About Akebia Therapeutics About Vadadustat Akebia Therapeutics Contact
SOURCE Akebia Therapeutics | ||
Company Codes: NASDAQ-NMS:AKBA |
View original content to download multimedia:
